Arpida, Inc. Falls as Iclaprim Fears Spark Cash Concerns

ZURICH Nov 19 (Reuters) - Shares in Swiss biotech company Arpida extended Tuesday's heavy losses on concerns the company may need to raise more cash if it fails to get U.S. approval for its antibiotic iclaprim, as some analysts predict.